Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.
Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Barni S, et al. Among authors: cappuzzo f. Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19. Lung Cancer. 2015. PMID: 26314614 Free article.
Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric Analysis.
Gallina FT, Chiappetta M, Tajè R, Forcella D, Sassorossi C, Congedo MT, Evangelista J, Sperduti I, Lococo F, Cappuzzo F, Melis E, Margaritora S, Facciolo F. Gallina FT, et al. Among authors: cappuzzo f. Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00039-1. doi: 10.1016/j.cllc.2024.03.004. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38627156 No abstract available.
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy.
Musicco F, Fulgenzio C, Malfa A, Jannitti N, Vitiello A, Carpano S, Fusco F, Cappuzzo F, Terrenato I, Sperduti I, Polidori P, Tarantino D, Cerbo LD, Pani M, Isgrò V, Lasala R. Musicco F, et al. Among authors: cappuzzo f. J Oncol Pharm Pract. 2024 Mar 27:10781552241242096. doi: 10.1177/10781552241242096. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38533561 Free article.
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Hong DS, Cappuzzo F, Chul Cho B, Dowlati A, Hussein M, Kim DW, Percent I, Christensen JG, Morin J, Potvin D, Faltaos D, Tassell V, Der-Torossian H, Chao R. Hong DS, et al. Among authors: cappuzzo f. Lung Cancer. 2024 Apr;190:107512. doi: 10.1016/j.lungcan.2024.107512. Epub 2024 Feb 22. Lung Cancer. 2024. PMID: 38417277 Clinical Trial.
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F, Di Carlo A, Spada S, Palermo B, D'Ambrosio L, D'Andrea D, Morello G, Belmonte B, Sperduti I, Balzano V, Gallo E, Melchionna R, Panetta M, Campo G, De Nicola F, Goeman F, Antoniani B, Carpano S, Frigè G, Warren S, Gallina F, Lambrechts D, Xiong J, Vincent BG, Wheeler N, Bortone DS, Cappuzzo F, Facciolo F, Tripodo C, Visca P, Nisticò P. Di Modugno F, et al. Among authors: cappuzzo f. EBioMedicine. 2024 Mar;101:105003. doi: 10.1016/j.ebiom.2024.105003. Epub 2024 Feb 9. EBioMedicine. 2024. PMID: 38340557 Free PMC article.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Passaro A, et al. Among authors: cappuzzo f. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879444 Free article. Clinical Trial.
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Marinelli D, et al. Among authors: cappuzzo f. Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. Crit Rev Oncol Hematol. 2023. PMID: 37871779 Free article.
309 results